HER2-POSITIVE ADVANCED BREAST CANCER
Clinical trials for HER2-POSITIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to break Cancer's growth signals
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-10203 in about 392 adults with advanced solid tumors (like breast, lung, or colorectal cancer) that have not responded to other treatments. The drug works by blocking a key cancer growth pathway. The main goals are to find the sa…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 26, 2026 10:33 UTC
-
PET scan could personalize breast cancer treatment after drug failure
Disease control Recruiting nowThis study is for people with advanced HER2-positive breast cancer whose disease has worsened after treatment with trastuzumab deruxtecan (T-DXd). Researchers will use a special PET scan (HER2-PET/CT) to see if the cancer still has HER2 targets. If the scan is positive, participa…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated May 26, 2026 10:25 UTC
-
New hope for advanced breast cancer: experimental drug combo enters final testing phase
Disease control Recruiting nowThis study tests a new drug called TQB2930 combined with chemotherapy for people with advanced HER2-positive breast cancer who have already tried at least two other anti-HER2 treatments. The goal is to see if TQB2930 works better than the standard drug trastuzumab (Herceptin) plu…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC